AxoGen Q3 revenue beats estimates on market expansion
Overview
US nerve repair device maker's Q3 revenue rose 26% yr/yr, beating analyst expectations
Adjusted net income for Q3 more than doubled from prior year
Company completed BioCircuit acquisition, funded by $225 mln public offering
Outlook
AxoGen expects 2026 revenue of at least $290 mln, including $7 mln from BioCircuit
Company expects 2026 organic revenue of at least $283 mln
AxoGen continues to expect 2026 gross margin of at least 73%
Result Drivers
MARKET EXPANSION - Co said broad-based revenue growth across Extremities, Oral Maxillofacial & Head and Neck, and Breast markets was driven by increased account productivity, expanded sales force coverage, and improved commercial insurance coverage and payment
INSURANCE COVERAGE - Co said positive coverage decisions from Elevance and Aetna increased commercial payer coverage for Avance to about 96% of covered lives in the US
BIOCIRCUIT ACQUISITION - Co completed acquisition of BioCircuit Technologies, using proceeds from public offering to fund purchase
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $75.80 mln | $73.20 mln (10 Analysts) |
Q3 Adjusted Net Income | $13.10 mln | ||
Q3 Net Income | $2.30 mln | ||
Q3 Adjusted EBITDA | $13.40 mln | ||
Q3 Gross Margin | 74.80% |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for AxoGen, Inc. is $53.00, about 41.5% above its October 27 closing price of $37.46
The stock recently traded at 55 times the next 12-month earnings vs. a P/E of 72 three months ago
Reuters Recommended Reads
Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption
Oct 28 - GE Healthcare Q3 profit beats estimates on advanced imaging segment
Oct 27 - Beta Bionics Q3 adjusted EBITDA misses estimates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)